安罗替尼联合程序性死亡蛋白-l抑制剂治疗晚期非小细胞肺癌患者的临床疗效

doi:10.3969/j.issn.1671-7171.2024.06.003

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1296 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the efficacy of anlotinib combined with programmed death-1(PD-1) inhibitor in the treatment of patients with advanced non-small cell lung cancer(NSCLC). 【Methods】A retrospective analysis was conducted on the clinical data of 90 NSCLC patients, who were divided into the control group(n=30, treated with anlotinib) and the observation group(n=60, treated with anlotinib combined with PD-1 inhibitor) based on different treatment methods. The short-term efficacy, survival, and drug safety of the two groups were compared. 【Results】After treatment, the objective response rate(ORR) in the observation group was 11.67%(7/60), and the disease control rate(DCR) was 60.00%(36/60), which were higher than those in the control group [ORR: 6.67%(2/30), DCR: 33.33%(10/30)], with statistically significant differences(P<0.05). The median progression-free survival(PFS) in the observation group was 10 months, and the median overall survival(OS) was 13 months. Both PFS and OS in the observation group were longer than those in the control group(median PFS: 7 months, median OS: 11 months), with statistically significant differences(P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05). 【Conclusion】The combination of anlotinib and PD-1 inhibitors in the treatment of advanced NSCLC can effectively improve the short-term efficacy and extend the survival time of patients.

Key words： Carcinoma, Non-Small-Cell Lung/DT Programmed Cell Death 1 Receptor/TU Treatment Outcome

Received: 20 January 2023

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Hui
	JIA Jing
	WANG Hui

Cite this article:

WANG Hui,JIA Jing,WANG Hui. Clinical Efficacy of Anlotinib Combined with PD-1 Inhibitor in the Treatment of Advanced Non-Small Cell Lung Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(6): 810-812.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2024.06.003 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2024/V41/I6/810

[1] 张殿宝,郝吉庆,张宪芬,等. LncRNA TUG1 调控 miR-142-5p/PD-L1 轴促进非小细胞肺癌细胞增殖、迁移与侵袭能力[J].临床与实验病理学杂志,2023,39(3):297-304.
[2] 杨光霞,程云涛,刘琳琳,等. 安罗替尼联合厄洛替尼治疗表皮生长因子受体突变阳性晚期非小细胞肺癌患者的临床研究[J].中国临床药理学杂志,2023,39(20):2905-2909.
[3] 王朝,韩雪,张爱霞. LIPI评分对PD-1/PD-L1抑制剂治疗非小细胞肺癌效果与预后的价值分析[J].中国现代医学杂志,2023,33(6):55-60.
[4] 何广思,王军,冯蒙蒙. 外周血细胞炎症标志物对晚期非小细胞肺癌免疫治疗预后的预测价值[J].国际肿瘤学杂志,2023,50(6):321-327.
[5] 中华医学会放射肿瘤治疗学分会, 中国医师协会放射肿瘤治疗医师分会, 中国抗癌协会放射治疗专业委员会,等.中国非小细胞肺癌放射治疗临床指南(2020版).中华放射肿瘤学杂志,2020,29(8):599.
[6] 白日兰,郭寒菲,崔久嵬,免疫治疗时代下肿瘤疗效的评价标准[J].国际肿瘤学杂志,2018,45(6):358.
[7] LI S,DE CAMARGO CORREIA G S, WANG J, et al. Emerging targeted therapies in advanced non-small-cell lung cancer[J].Cancers,2023, 15(11): 2899.
[8] 赵硕,王欣. 血浆心脏型脂肪酸结合蛋白对非小细胞肺癌诊断和预后的价值研究[J].海军医学杂志,2023,44(3):246-250.
[9] 武阳,陆翰杰,水会锋. 既往免疫经治的晚期非小细胞肺癌患者接受安罗替尼联合PD-1单抗的疗效及安全性[J].实用医学杂志,2023,39(5):572-578.
[10] 钱磊,冯继锋. 晚期非小细胞肺癌抗血管生成联合免疫治疗的理论基础及临床应用研究进展[J].山东医药,2020,60(15):95-98.
[11] 潘晓葶,戴安伟. 安罗替尼联合PD-1单抗三线及以上治疗晚期非小细胞肺癌的疗效和安全性[J].现代肿瘤医学,2023,31(16):3024-3027.
[12] 张萌萌,黄玮,笪良山,等. 安罗替尼三线及以上治疗晚期非小细胞肺癌的疗效及安全性[J].临床与病理杂志,2022,42(3):571-576.
[13] 齐心,刘佳,封元清,等. 免疫跨线联合安罗替尼三线治疗晚期非小细胞肺癌近远期疗效观察[J].肿瘤综合治疗电子杂志,2023,9(3):93-97.
[14] 刘雨晴,袁淑敏,祁晓星,等. 安罗替尼联合免疫检查点抑制剂治疗晚期非小细胞肺癌的疗效及安全性[J].中国临床医生杂志,2023,51(4):447-450.